Ontology highlight
ABSTRACT:
SUBMITTER: Tajima H
PROVIDER: S-EPMC5844031 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
Tajima Hidehiro H Okazaki Mitsuyoshi M Yamaguchi Takahisa T Ohbatake Yoshinao Y Okamoto Koichi K Nakanuma Shinichi S Terai Shiro S Sakai Seisho S Kinoshita Jun J Makino Isamu I Nakamura Keishi K Hayashi Hironori H Oyama Katsunobu K Inokuchi Masafumi M Miyashita Tomoharu T Takamura Hiroyuki H Ninomiya Itasu I Fushida Sachio S Ohta Tetsuo T
Molecular and clinical oncology 20180220 4
The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The present study conducted a Phase I clinical trial of weekly low-dose PTX as a third-line palliative chemotherapy for patients with pancreatic cancer. PTX was administered on days 1, 8, 15, and 22 of each cy ...[more]